Maria Gabriela Pittis – Head of South Cone, Andean Region, Mexico & Central America and Caribbean, Takeda

Maria Gabriela Pittis Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company's significant presence in the cluster, its double digit growth and plans to launch 14 new products there by 2025, most importantly its European Medicines Agency-approved dengue vaccine. She also explains the shift that Takeda has undergone in LatAm since the acquisition of Shire, bringing onboard a large rare diseases portfolio as well as a plasma-derived unit.  
[The dengue vaccine] is a momentous achievement for Takeda and will have a big impact on LatAm, which – along with Asia – is home to many of the endemic regions for dengue.
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report